- Home
- CIM vs GHRS Comparison
CIM vs GHRS Comparison
Compare CIM & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIM
- GHRS
- Stock Information
- Founded
- CIM 2007
- GHRS 2018
- Country
- CIM United States
- GHRS Ireland
- Employees
- CIM N/A
- GHRS N/A
- Industry
- CIM Real Estate Investment Trusts
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- CIM Real Estate
- GHRS Health Care
- Exchange
- CIM Nasdaq
- GHRS Nasdaq
- Market Cap
- CIM 1.1B
- GHRS 925.2M
- IPO Year
- CIM 2007
- GHRS 2021
- Fundamental
- Price
- CIM $14.12
- GHRS $15.58
- Analyst Decision
- CIM Buy
- GHRS Strong Buy
- Analyst Count
- CIM 3
- GHRS 8
- Target Price
- CIM $15.50
- GHRS $30.63
- AVG Volume (30 Days)
- CIM 561.8K
- GHRS 187.7K
- Earning Date
- CIM 08-06-2025
- GHRS 09-02-2025
- Dividend Yield
- CIM 10.52%
- GHRS N/A
- EPS Growth
- CIM N/A
- GHRS N/A
- EPS
- CIM 1.52
- GHRS N/A
- Revenue
- CIM $326,755,000.00
- GHRS N/A
- Revenue This Year
- CIM $18.94
- GHRS N/A
- Revenue Next Year
- CIM $3.05
- GHRS N/A
- P/E Ratio
- CIM $9.26
- GHRS N/A
- Revenue Growth
- CIM 11.90
- GHRS N/A
- 52 Week Low
- CIM $9.85
- GHRS $6.00
- 52 Week High
- CIM $16.89
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- CIM 55.31
- GHRS 67.14
- Support Level
- CIM $14.09
- GHRS $14.20
- Resistance Level
- CIM $14.43
- GHRS $15.54
- Average True Range (ATR)
- CIM 0.25
- GHRS 1.07
- MACD
- CIM -0.03
- GHRS 0.29
- Stochastic Oscillator
- CIM 59.24
- GHRS 93.84
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.